Patent · US Active

Use of C2-substituted indan-1-ol systems for preparing medicaments for the prophylaxis or treatment of obesity

US7763662B2 · kind B2 · utility

0Cited by

5References

24Claims

0Family size

Assignee

Sanofi-Aventis Deutschland GMBH · DE

Inventors

Gerhard Jaehne · Frankfurt, DE
Volker Krone · Flörsheim, DE
Martin Bickel · Frankfurt am Main, DE
Matthias Gossel · Frankfurt am Main, DE

Key dates

Filing date	Dec 7, 2004
Grant date	Jul 27, 2010
Priority date	—
Expiry date	Jun 26, 2028

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Embodiments of the invention relate to methods of reducing weight in mammals and for the prophylaxis or treatment of obesity comprising administration of C2-substituted indan-1-ol systems and their physiologically acceptable salts and physiologically functional derivatives. Compounds for use in the methods of the embodiments of the invention include compounds of the formula (I)in which the radicals are as defined, and their physiologically acceptable salts.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.